LXR Agonists - A crucial role in cholesterol metabolism and inflammation
Liver X receptors LXRα and LXRβ are attractive, but challenging drug targets from the nuclear receptor family. As they have a critical role in cholesterol metabolism and (reverse) transport, lipogenesis, glucose homeostasis, inflammation and innate immunity, they have been explored as promising targets in a number of indications such as atherosclerosis, diabetes, cancer, Alzheimer's, and inflammation. However, existing compounds often lead to serious side effects. Lead Pharma has developed a series of LXR agonists. Their properties offer a unique opportunity to develop safe and efficacious LXR agonists for the topical treatment of skin diseases and the opportunity of an increased therapeutic window.